Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CM4620
CM4620-IE · 1 trial · 1 indication
Outcome assessed the percent change in IL-2 production after the administration of a single dose of CM4620-IE as compared to baseline production, for all patients enrolled. This measurement was to explore if there was a change in IL-2 levels with acute pancreatitis after the administration of a single dose of CM4620-IE.
| Arm | Type | Description |
|---|---|---|
| All Patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CM4620-IE | DRUG | single IV infusion on Day 1 over 4 hours |
Inclusion Criteria: 1. Diagnosis of acute pancreatitis established by the presence of abdominal pain consistent with acute pancreatitis, and 1 of the following 2 criteria: 1. Serum lipase and/or serum amylase \> 3 times the upper limit of normal (ULN); 2. Characteristic findings of acute pan...
CM4620-IE is an investigational small molecule developed by CalciMedica, Inc. (ticker CALC) for acute pancreatitis. It is a Phase 2 drug candidate and has been studied in a completed clinical trial. It is not described as approved, so it remains in clinical development.
CM4620-IE is being developed for the treatment of acute pancreatitis, a gastrointestinal condition. CalciMedica, Inc. is studying it in this indication. The program has completed a Phase 2 trial, and the drug is investigational rather than an approved therapy for acute pancreatitis.
CM4620-IE targets Orai1, a component of the CRAC channel, which is a calcium release-activated calcium channel. By acting on this target class, the small molecule is designed to modulate CRAC channel activity. CalciMedica, Inc. is developing CM4620-IE around this mechanism for acute pancreatitis.
CM4620-IE is being developed by CalciMedica, Inc., which trades under the ticker CALC. The company is the sponsor of the clinical program for this small molecule in acute pancreatitis. No other developer or partnership is associated with the asset in the available program information.
CM4620-IE is in Phase 2 development. Its single clinical trial, NCT03709342, was a Phase 2 PK/PD study in patients with acute pancreatitis that has been completed. The drug is investigational and is not described as FDA approved.
CM4620-IE has been studied in one clinical trial, NCT03709342, titled A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis. It was a completed Phase 2 study conducted in the United States with 7 enrolled patients, ages 18 years and older, and it was uncontrolled.